Skip to main content
. 2022 Mar 22;7(6):e154395. doi: 10.1172/jci.insight.154395

Figure 3. Clinical and patient-reported characteristics of CIPN in patients.

Figure 3

(A) Chemotherapy but not control patients developed an increase in the Total Neuropathy Score reduced (TNSr). (B) Patient-reported symptoms of CIPN, assessed with the EORTC-CIPN20 questionnaire, increased in chemotherapy-treated patients. (C) The increase in subjective CIPN symptoms was significantly greater in chemotherapy than control patients, (D) particularly for the sensory symptoms of CIPN assessed with the questionnaire, whereas (E) only a slight nonsignificant increase was observed for motor symptoms and (F) autonomic symptoms. (G) Change in subjective CIPN symptoms correlated well with the increase in TNSr, which (H) was also the case for only the sensory items of the CIPN20 questionnaire (area filling indicates 95% CI). (I) The Karnofsky performance index decreased in chemotherapy-treated patients but not in controls. Statistical analysis: (A–F and I) Kruskal-Wallis test with Dunn’s post hoc correction; (G and H) linear regression with Spearman’s correlation. Study participants: (A and I) n = 6 (healthy), n = 25 (control), n = 31 (chemo); (B–H) n = 4 (healthy), n = 24 (control), n = 29 (chemo). *P < 0.05, **P < 0.01, ****P < 0.0001.